Does a preoperative subconjunctival injection of Dexamethason reduce the incidence of proliferative vitreoretinopathy in patients with ablatio retinae?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21185

Enrollment

Registered

2005-08-23

Start date

2002-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Preoperative and postoperative subconjunctival injection of Dexamethasone (10 mg) or placebo.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Primary rhegmatogenous retinal detachment; 2. No previous ablatio surgery.

Exclusion criteria

Exclusion criteria: 1. Diabetes mellitus; 2. Systemic steroids; 3. Steroid eye drops; 4. Steroid glaucoma responder.

Design outcomes

Primary

Measure	Time frame
Incidence of proliferative vitreoretinopathy.	—

Contacts

Public ContactJ.C. Meurs, van

Oogziekenhuis Rotterdam, Schiedamsevest 180

vanMeurs@oogziekenhuis.nl+31 (0)10 4017777

Outcome results